
According to data from Benzinga Pro, during Q4, VYNE Therapeutics's (NASDAQ:VYNE) reported sales totaled $2.29 million. Despite a 45.64% increase in earnings, the company posted a loss of $11.57 million. In Q3, VYNE Therapeutics brought in $4.09 million in sales but lost $21.29 million in earnings.